Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;36(12):905-914.
doi: 10.1016/j.tig.2020.09.011. Epub 2020 Oct 8.

Anticipating and Identifying Collateral Damage in Genome Editing

Affiliations
Review

Anticipating and Identifying Collateral Damage in Genome Editing

Gaëtan Burgio et al. Trends Genet. 2020 Dec.

Abstract

Genome editing has powerful applications in research, healthcare, and agriculture. However, the range of possible molecular events resulting from genome editing has been underestimated and the technology remains unpredictable on, and away from, the target locus. This has considerable impact in providing a safe approach for therapeutic genome editing, agriculture, and other applications. This opinion article discusses how to anticipate and detect those editing events by a combination of assays to capture all possible genomic changes. It also discusses strategies for preventing unwanted effects, critical to appraise the benefit or risk associated with the use of the technology. Anticipating and verifying the result of genome editing are essential for the success for all applications.

Keywords: ectopic insertions; genome editing; off-target activity; on-target activity; validation.

PubMed Disclaimer

Figures

Figure1:
Figure1:. Possible outcomes of Cas9 double stranded break of the DNA:
Cas9 induced double stranded break leads to a series of expected and unexpected outcomes. Final editing outcome results in small insertions, deletions or chromosomal translocations or incomplete template integration.

References

    1. Pickar-Oliver A and Gersbach CA (2019) The next generation of CRISPR–Cas technologies and applications. Nat. Rev. Mol. Cell Biol 20, 490–507 - PMC - PubMed
    1. Hajizadeh Dastjerdi A et al. (2019) The Expanding Class 2 CRISPR Toolbox: Diversity, Applicability, and Targeting Drawbacks. BioDrugs Clin. Immunother. Biopharm. Gene Ther 33, 503–513 - PubMed
    1. Zhang Y et al. (2018) Applications and potential of genome editing in crop improvement. Genome Biol. 19, 210. - PMC - PubMed
    1. Stadtmauer EA et al. (2020) CRISPR-engineered T cells in patients with refractory cancer. Science DOI: 10.1126/science.aba7365 - DOI - PMC - PubMed
    1. Hamilton JR and Doudna JA (2020) Knocking out barriers to engineered cell activity. Science DOI: 10.1126/science.aba9844 - DOI - PubMed

Publication types